Journals / Türkderm Türk deri hastalıkları ve frengi arşivi / 2020 / Cilt: 54 - Sayı: 1

Treatment of tuberous sclerosis facial angiofibromas with erbium-yttrium aluminium garnet laser and topical sirolimus 0.25%

Tüberoskleroz yüz anjiyofibromlarının erbium-itriyum alüminyum garnet lazer ve topikal sirolimus %0,25 ile tedavisi

Pages
19–21
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We combined the full-field erbium-yttrium aluminium garnet laser application with topical sirolimus 0.25% cream on the second month of treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although the efficacy of topical sirolimus for facial angiofibromas of tuberosclerosis is now appreciated, drug-induced irrritation complicates the use of the concentration recommended in the literature as 1%.
📊
Key Findings & Data:Herein, we aimed to share the 2-year follow up result of a tuberoussclerosis case where angiofibromas were observed on the chin, malar regions and nose.
💡
Conclusion & Impact:We combined the full-field erbium-yttrium aluminium garnet laser application with topical sirolimus 0.25% cream on the second month of treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Although the efficacy of topical sirolimus for facial angiofibromas of tuberosclerosis is now appreciated, drug-induced irrritation complicates the use of the concentration recommended in the literature as 1%. Adjuvant vascular or ablative laser applications may be preferred in adult patients for a variety of purposes, such as treatment of large lesions that tend to be resistant to topical treatment, reduction of topical product concentration and rapid response generation. Herein, we aimed to share the 2-year follow up result of a tuberoussclerosis case where angiofibromas were observed on the chin, malar regions and nose. We combined the full-field erbium-yttrium aluminium garnet laser application with topical sirolimus 0.25% cream on the second month of treatment.

Özet

Tüberosklerozun yüz yerleşimli anjiyofibromlarında topikal sirolimusun etkinliği artık iyi bilinmekle birlikte ilaca bağlı irritasyon literatürde önerilen%1 konsantrasyonun kullanımını zorlaştırmaktadır. Adjüvan vasküler veya ablatif lazer uygulamaları, topikal tedaviye dirençli olma eğilimigösteren büyük lezyonların tedavisi, kullanılan topikal ürün derişiminin azaltılması ve hızlı yanıt eldesi gibi çeşitli amaçlar için erişkin hastalardatercih edilebilir. Biz burada çene, burun, malar bölgelerde yaygın yerleşimli anjiyofibroma lezyonları izlenen bir tüberoskleroz olgumuzun 2 yıllıktakip sonucunu paylaşmayı amaçladık. Bu olgunun yönetiminde tüm-saha erbium-itriyum alüminyum garnet lazer uygulamasını, tedavi sonrasıikinci ayda %0,25 dozda topikal sirolimus kullanımı ile kombine ettik.

🔖

Cite This Article

BOTSALI, A., ÇALIŞKAN, E., KÜÇÜK, K., GAHRAMANOV, İ., ÖZKAN, C. K. (2022). Treatment of tuberous sclerosis facial angiofibromas with erbium-yttrium aluminium garnet laser and topical sirolimus 0.25%. Türkderm Türk deri hastalıkları ve frengi arşivi, Cilt: 54 - Sayı: 1, 19–21. https://ajindex.com/articles/622490

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Salido-Vallejo R, Garnacho-Saucedo G, Moreno-Gimenez JC. Current options for the treatment of facial angiofibromas. Actas Dermosifiliogr 2014;105:558-68.
  2. Balestri R, Neri I, Patrizi A, Angileri L, Ricci L, Magnano M: Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex. J Eur Acad Dermatol Venereol 2015;29:14-20.
  3. Zachary CB, Rofagha R: Laser therapy. Ablative lasers: Carbon dioxide and Er: YAG. Ed. Bolognia J. Dermatology, 2012.
  4. Pasyk KA, Argenta LC: Argon laser surgery of skin lesions in tuberous sclerosis. Ann Plast Surg 1988;20:426-33.
  5. Ali FR, Mallipeddi R, Craythorne EE, Sheth N, Al-Niaimi F: Our experience of carbon dioxide laser ablation of angiofibromas: Case series and literature review. J Cosmet Laser Ther 2016;18:372-5.
  6. Koenig MK, Bell CS, Hebert AA, et al: Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: The TREATMENT randomized clinical trial. JAMA Dermatol 2018;154:773-80.
  7. Bae-Harboe YS, Geronemus RG. Targeted topical and combination laser surgery for the treatment of angiofibromas. Lasers Surg Med 2013;45:555-7.
  8. Park J, Yun SK, Cho YS, Song KH, Kim HU: Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical rapamycin and concomitant laser therapy. Dermatology 2014;228:37-41.
  9. Negosanti F, Tengattini V, Gurioli C, Neri I: Facial angiofibromas treated by rapamycin 0.05% ointment and a combined laser therapy. J Cosmet Dermatol 2018;17:762-5.
  10. Fioramonti P, De Santo L, Ruggieri M, et al: Co2/Erbium:YAG/Dye laser combination: An effective and successful treatment for angiofibromas in tuberous sclerosis. Aesthetic Plast Surg 2014;38:192-8.